Pathology, research and practice最新文献

{"title":"Whole genome profiling of rare pediatric thoracic tumors elucidates a YAP1::LEUTX fusion in an unclassified biphasic embryonal neoplasm","authors":"Georgi Lukose ,&nbsp;Majd Al Assaad ,&nbsp;Jordan H. Driskill ,&nbsp;Max F. Levine ,&nbsp;Gunes Gundem ,&nbsp;Alissa Semaan ,&nbsp;David C. Wilkes ,&nbsp;Nitsana A. Spigland ,&nbsp;Juan S. Medina-Martínez ,&nbsp;Andrea Sboner ,&nbsp;Olivier Elemento ,&nbsp;José Jessurun ,&nbsp;Juan Miguel Mosquera","doi":"10.1016/j.prp.2024.155726","DOIUrl":"10.1016/j.prp.2024.155726","url":null,"abstract":"<div><div>Malignant biphasic tumors of the lungs are rare, more so in the pediatric population. Here, we present the whole-genome characterization of a pleuropulmonary blastoma Type III and an unclassified biphasic thoracic embryonal neoplasm. The pleuropulmonary blastoma harbored pathogenic <em>DICER1</em> germline and somatic mutations, and additional somatic variants in <em>TP53</em> and <em>BCOR</em>. The other malignant tumor demonstrated a t(11;19) balanced translocation with a <em>YAP1::LEUTX</em> fusion that was confirmed by fluorescence <em>in situ</em> hybridization. No <em>DICER1</em> germline or somatic mutation was present. <em>YAP1</em> and <em>LEUTX</em> have been implicated in tumorigenesis of various neoplasms, and <em>YAP1</em> fusion genes are an emerging oncogenic entity in a variety of malignancies. In this study we highlight the importance of whole-genome characterization of rare and unclassified tumors to identify biologic mechanisms and potential therapeutic targets.</div></div>","PeriodicalId":19916,"journal":{"name":"Pathology, research and practice","volume":"264 ","pages":"Article 155726"},"PeriodicalIF":2.9,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142682387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of three specimen collection techniques in tissue coagulum clot-based cell block preparation of endobronchial ultrasound-guided transbronchial needle aspiration","authors":"Zeyun Lin ,&nbsp;Lixi Huang ,&nbsp;Shiqi Tang ,&nbsp;Anzi Tan ,&nbsp;Chunli Tang ,&nbsp;Yingying Gu ,&nbsp;Jiangyu Zhang ,&nbsp;Juhong Jiang","doi":"10.1016/j.prp.2024.155730","DOIUrl":"10.1016/j.prp.2024.155730","url":null,"abstract":"<div><h3>Objectives</h3><div>The performance of cell blocks (CBs) can vary significantly depending on the specimen collection and processing techniques used. This study compared the efficiency of three distinct specimen collection methods for endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) samples.</div></div><div><h3>Materials and methods</h3><div>From June 2021 to June 2023, the study involved 1450 patients who underwent EBUS-TBNA, resulting in the sampling of 1941 lesions. For these samples, three distinct specimen processing methods were employed to prepare tissue coagulum clot-based CBs. Specifically, the filter paper method was employed in 470 cases (yielding 626 samples), the centrifugation method in 500 cases (yielding 673 samples), and the funnel filtration method in 480 cases (yielding 642 samples).</div></div><div><h3>Results</h3><div>Out of these 1941 samples, the diagnostic yield for samples obtained using filter paper, centrifugation, and funnel filtration methods was 84.7 %, 87.7 %, and 92.5 %, respectively. In the subgroup of patients diagnosed with non-small cell lung cancer, the adequacy rate for molecular testing in samples processed through filter paper, centrifugation, and funnel filtration methods was 57.7 %, 82.0 %, and 88.3 %, respectively. In the centrifugation group, the combination of the CBs and cell pellet achieved an adequacy rate of 96.5 %.</div></div><div><h3>Discussion</h3><div>The cellular yield of CBs from EBUS-TBNA was significantly enhanced using centrifugation and funnel filtration methods. The funnel filtration method offered a more convenient and cost-effective approach, reducing cellular loss due to sample dispersion in the fixative medium. The use of the centrifugation method to prepare CBs, along with the retrieval of cell pellets from the residual fixative medium, can maximize the specimen adequacy rate for molecular testing.</div></div>","PeriodicalId":19916,"journal":{"name":"Pathology, research and practice","volume":"265 ","pages":"Article 155730"},"PeriodicalIF":2.9,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142695755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “A review on the role of KCNQ1OT1 lncRNA in human disorders” [Pathol. - Res. Pract. 255 (2024) 155188]","authors":"Mohammad Taheri ,&nbsp;Zeinab Shirvani-Farsani ,&nbsp;Atefeh Harsij ,&nbsp;Mohadeseh Fathi ,&nbsp;Sheyda Khalilian ,&nbsp;Soudeh Ghafouri-Fard ,&nbsp;Aria Baniahmad","doi":"10.1016/j.prp.2024.155723","DOIUrl":"10.1016/j.prp.2024.155723","url":null,"abstract":"","PeriodicalId":19916,"journal":{"name":"Pathology, research and practice","volume":"264 ","pages":"Article 155723"},"PeriodicalIF":2.9,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142639436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of trophoblast cell surface antigen-2 (TROP2) protein expression in chemotherapy-resistant and metastatic breast carcinomas","authors":"Mieke R. Van Bockstal ,&nbsp;Marie-Caroline Depelsemaeker ,&nbsp;Lina Daoud ,&nbsp;Quitterie Fontanges ,&nbsp;Aline Francois ,&nbsp;Yves Guiot ,&nbsp;Anne-France Dekairelle ,&nbsp;Dominique Dubois ,&nbsp;Cédric Van Marcke ,&nbsp;Eléonore Longton ,&nbsp;Francois P. Duhoux ,&nbsp;Hilde Vernaeve ,&nbsp;Martine Berlière ,&nbsp;Giuseppe Floris ,&nbsp;Christine Galant","doi":"10.1016/j.prp.2024.155724","DOIUrl":"10.1016/j.prp.2024.155724","url":null,"abstract":"<div><div>Trophoblast cell-surface antigen 2 (TROP2), a transmembrane receptor expressed in many carcinomas, is a target for novel antibody-drug conjugates such as sacituzumab govitecan. TROP2-targeted therapy is used for unresectable locally advanced or metastatic triple-negative and hormone receptor-positive, HER2-negative breast cancers. The role of TROP2 as a predictive marker is yet unclear. Standardized interpretation criteria for TROP2 immunohistochemistry (IHC) are lacking. Here, we compared three antibody clones and two methods for semi-quantitative assessment, aiming to establish reproducible evaluation criteria. First, TROP2 IHC was performed on normal tissues and nine breast cancers, using the BSB-148, EPR20043 and SP293 clones. EPR20043 was selected for subsequent evaluation in 69 breast cancers without pathological complete response to neoadjuvant chemotherapy (NAC). Four pathologists applied the ASCO/CAP guidelines for HER2 IHC testing (designated as the ‘membrane score’) and the H-score. All H-scores were categorized as low (0−100), intermediate (101−200) and high (201−300). Although the membrane scores strongly correlated with the categorized H-scores, the latter showed higher interobserver variability. Next, TROP2 IHC was performed on 94 breast cancer metastases and evaluated by six pathologists, confirming the strong correlation between the membrane scores and H-scores. In metastases, the interobserver variability was similar for both methods. Our observations support the application of the HER2 ASCO/CAP guidelines for semi-quantitative evaluation of membranous TROP2 protein expression, as this method strongly correlates with the H-score and is less prone to interobserver variability in post-NAC breast resections. Future studies should investigate the association between the TROP2 membrane score and response to TROP2-targeted therapy.</div></div>","PeriodicalId":19916,"journal":{"name":"Pathology, research and practice","volume":"264 ","pages":"Article 155724"},"PeriodicalIF":2.9,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142687664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of PDCD6 in stemness maintenance of Glioblastoma","authors":"Xiyu Liu ,&nbsp;Zuolin Shi ,&nbsp;Xuantong Liu ,&nbsp;Yuan Cao ,&nbsp;Xinyu Yang ,&nbsp;Jiaming Liu ,&nbsp;Tianqi Xu ,&nbsp;Weiyi Yang ,&nbsp;Ligang Chen ,&nbsp;Zheng Zou ,&nbsp;Qingge Jia ,&nbsp;Mingyang Li","doi":"10.1016/j.prp.2024.155727","DOIUrl":"10.1016/j.prp.2024.155727","url":null,"abstract":"<div><h3>Background</h3><div>Glioblastoma (GBM) poses formidable challenges due to its high malignancy and therapeutic resistance and still exhibits dismal 5-year survival rates, high recurrence propensity, and limited treatment modalities. There is an acute need for innovative treatments for recurrent glioblastoma due to the lack of established protocols. This necessity is driving research into the cellular underpinnings that initiate and drive the disease forward, aiming to discover groundbreaking targets for therapy that could enhance the efficacy of medical interventions.</div></div><div><h3>Methods</h3><div>Patient-derived glioblastoma stem cells (GSCs) were harvested and isolated. Subsequently, PDCD6 expression was quantified through both western blotting (WB) and real-time PCR (RT-PCR) techniques. The stem-like properties of the GSCs were evaluated using sphere-forming assays. All gathered data, inclusive of TCGA datasets, were analyzed using SPSS (IBM) version 23.0.</div></div><div><h3>Results</h3><div>Elevated PDCD6 expression characterized classical GBM tumor tissues. PDCD6 overexpression significantly correlated with diminished overall survival in GBM patients, emerging as an independent prognostic indicator. Notably, primary GBM cells exhibited heightened PDCD6 levels in GSCs compared to NSTCs. Moreover, alterations in stemness markers paralleled PDCD6 modulation, where PDCD6 knockdown attenuated tumor size in GSCs.</div></div><div><h3>Conclusion</h3><div>Our findings illuminate PDCD6's role in fostering stemness within classical GBM, hinting at its potential as a therapeutic target.</div></div>","PeriodicalId":19916,"journal":{"name":"Pathology, research and practice","volume":"264 ","pages":"Article 155727"},"PeriodicalIF":2.9,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142676651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clear cell stromal tumor of the lung: Report of 3 cases with emphasis on multifocal tumors","authors":"Annikka Weissferdt,&nbsp;Cesar A. Moran","doi":"10.1016/j.prp.2024.155722","DOIUrl":"10.1016/j.prp.2024.155722","url":null,"abstract":"<div><div>We describe 3 patients with clear cell stromal tumor (CCST) of the lung, all of whom presented with multifocal disease. The patients were 2 men and 1 woman aged 47–58 years (mean, 54 years). Two patients had evidence of autoimmune disease and their pulmonary disease was an incidental finding; one patient presented with non-specific respiratory symptoms. Radiologic imaging revealed multiple pulmonary nodules in all patients. Histologically, the tumors were solid-cystic and composed of cytologically bland, medium-sized ovoid to spindle cells with eosinophilic to clear cytoplasm arranged in a subtle nested pattern. These tumor cells were set in a highly vascularized stroma. Occasional cytologic atypia with multinucleated tumor cells was noted but mitotic activity was low. An infiltrate of mixed inflammatory cells was apparent in all tumors. Immunohistochemical analysis demonstrated diffuse expression of vimentin and TFE3 in all cases. Next generation sequencing revealed the presence of <em>YAP1::TFE3</em> fusion in 1/1 case. All patients have remained alive albeit with stable or progressive disease, 24–66 months after diagnosis. These cases highlight the existence of multifocal pulmonary CCST and seem to support the notion that multifocality in CCST may be associated with more protracted clinical course. Awareness of the existence of multifocal pattern is important for patient management and prognosis.</div></div>","PeriodicalId":19916,"journal":{"name":"Pathology, research and practice","volume":"264 ","pages":"Article 155722"},"PeriodicalIF":2.9,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142661981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation between immune microenvironment and clinicopathological characteristics and prognosis of primary large B-cell lymphoma of immune-privileged sites","authors":"Yawen Guo,&nbsp;Xiaoxian Zhang,&nbsp;Luyao Wu,&nbsp;Jiajia Ma,&nbsp;Ran Zhang,&nbsp;Huifang Yan,&nbsp;Xinxia Li","doi":"10.1016/j.prp.2024.155720","DOIUrl":"10.1016/j.prp.2024.155720","url":null,"abstract":"<div><h3>Objectives</h3><div>To explore the correlation between tumor-associated macrophages (TAMs), tumor-infiltrating lymphocytes (TILs), and tumor-associated angiogenesis (TAA) in the tumor microenvironment with the clinicopathological characteristics and prognosis of primary large B-cell lymphoma of immune-privileged sites (LBCL-IP).</div></div><div><h3>Methods</h3><div>A total of 46 cases of LBCL-IP from the Department of Pathology, the Third Affiliated Hospital of Xinjiang Medical University, from January 2010 to February 2024, were collected, along with clinical and follow-up data of LBCL-IP patients. Immunohistochemistry and triple immunofluorescence were used to detect related proteins of TAMs, TILs, and TAA, and to analyze the correlation between TAMs, TILs, TAA, and the polarization of TAMs with the clinical and prognostic factors of LBCL-IP patients.</div></div><div><h3>Results</h3><div>There are 30 cases (65.2 %) showed high expression of CD68 proteins, 32 cases (69.6 %) showed high expression of CD163 proteins, 19 cases (41.3 %) showed high expression of CD4 proteins, 34 cases (73.9 %) showed high expression of CD8 proteins, and 25 cases (54.3 %) showed high expression of CD34 proteins. A total of 28 cases (60.9 %) showed CD68⁺CD163⁺/CD68⁺CD86⁺≥1. The chi-square tests showed that high expression of CD163 proteins was positively correlated with elevated LDH and BMG values, and the count of CD68⁺CD163⁺/CD68⁺CD86⁺≥1 was positively correlated with ECOG scores ≥2, Ann Arbor staging III-IV, and increased BMG value. High expression of CD8 proteins was positively correlated with a Ki-67 proliferation index ≥70 %, and high MVD values were positively correlated with Ann Arbor staging III-IV. The Kaplan-Meier estimator analysis showed that LBCL-IP patients with low expression of CD68 proteins, high expression of CD163 proteins, CD68⁺CD163⁺/CD68⁺CD86⁺≥1, low expression of CD8 proteins, high MVD values, ECOG scores ≥2, Ann Arbor staging III-IV, LDH ≥250 U/L, BMG ≥2.2 mg/L, and IPI scores ≥2 had shorter survival times. Multivariate Cox regression analysis showed that low expression of CD8 proteins, CD68⁺CD163⁺/CD68⁺CD86⁺≥1, LDH ≥250 U/L, and ECOG scores ≥2 are independent risk factors affecting the survival of LBCL-IP patients.</div></div><div><h3>Conclusion</h3><div>M2-polarized TAMs and low infiltration of CD8⁺ TILs were more strongly correlated with poor clinical pathological indicators and worse prognosis, and MVD values may serve as an aiding means for the diagnosis and prognostic prediction of LBCL-IP disease.</div></div>","PeriodicalId":19916,"journal":{"name":"Pathology, research and practice","volume":"264 ","pages":"Article 155720"},"PeriodicalIF":2.9,"publicationDate":"2024-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142625774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Germline pathogenic variants in prostate cancer","authors":"Yousif M. Shakroo ,&nbsp;Charles A. Seabury Jr. ,&nbsp;Kenneth A. Iczkowski ,&nbsp;Kinloch Nelson ,&nbsp;Junqi Qian ,&nbsp;Dharam M. Ramnani","doi":"10.1016/j.prp.2024.155718","DOIUrl":"10.1016/j.prp.2024.155718","url":null,"abstract":"<div><div>While most prostate cancer is sporadic, evidence suggests that a significant minority of cases have a hereditary component, and germline variants may play a role in this heritability. In this study, we investigated germline pathogenic variants in prostate cancer patients. All genetic variants were classified using the American College of Medical Genetics and Genomics/Association for Molecular Pathology 2015 guidelines. By retrospectively reviewing patient charts and genetic testing results, we collected clinicopathologic, demographic, and genetic data. Among the 160 prostate cancer patients who met NCCN genetic testing guidelines and underwent germline testing, 41 % had metastatic cancer, while 59 % had localized cancer, mostly high-risk. Nineteen (19) out of the 160 patients (12 %) had a pathogenic or likely pathogenic variant in the following genes: <em>MUTYH</em> (3.1 %), <em>ATM</em> (1.9 %), <em>BRCA2</em> (1.3 %), <em>CHEK2</em> (1.3 %), <em>PALB2</em> (1.3 %), <em>HOXB13</em> (1.3 %), and 5 other genes (<em>BRIP1</em>, <em>LZTR1</em>, <em>TP53</em>, <em>NTHL1</em>, and <em>NBN</em>), each at a frequency of 0.6 %. There was no significant difference in clinicopathologic data (such as age, serum prostate-specific antigen, Gleason score, and others) between those with a pathogenic or likely pathogenic variant and those without. There was also a lack of significant difference in the number of variants of uncertain significance observed between different racial and ethnic groups. Individuals with a family history of cancer were significantly more likely to have a pathogenic or likely pathogenic variant than those without one (p = 0.002). Overall, our results show the necessity for future research with a larger sample size to better explain the relationship between clinicopathologic data and genetic variants.</div></div>","PeriodicalId":19916,"journal":{"name":"Pathology, research and practice","volume":"264 ","pages":"Article 155718"},"PeriodicalIF":2.9,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142625791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"BCL11A expression worsens the prognosis of DLBCL and its co-expression with C-MYC predicts poor survival","authors":"Lixin Wang ,&nbsp;Hong He ,&nbsp;Yuanxin Li ,&nbsp;Xingyu Wang ,&nbsp;Jieyang Yu ,&nbsp;Ying Huang ,&nbsp;Kuai Yu ,&nbsp;Juan He ,&nbsp;Min Zhao ,&nbsp;Tao Xie ,&nbsp;Dan Li","doi":"10.1016/j.prp.2024.155717","DOIUrl":"10.1016/j.prp.2024.155717","url":null,"abstract":"<div><div>Non-Hodgkin's lymphoma (NHL) is a significant global malignancy, with diffuse large B cell lymphoma (DLBCL) being the most prevalent subtype, accounting for 25–50 % of newly diagnosed cases in China. Despite a 60 % survival rate achieved with R-CHOP regiment for DLBCL, approximately 40 % of patients experience relapse or develop resistance to treatment. While the oncogenic transcription factor B-cell chronic lymphocytic leukaemia/lymphoma 11 A (BCL11A) has been implicated in various tumors, its specific role in DLBCL remains unclear. In this study, we conducted retrospective histomorphological and immunophenotypic analyses on paraffin sample tissues and collected fresh tissue samples for protein and mRNA analyses to investigate the relationship between BCL11A and DLBCL. Additionally, we classified DLBCL into subtypes based on cells of origin (COO) and examined the expressions of BCL11A, C-MYC, P53 and other protein expressions to better understand the factors contributing to poor clinical outcomes in DLBCL. Our findings revealed elevated BCL11A expression in DLBCL, with increased expression associated with worse prognosis and higher C-MYC expression. Patients exhibiting co-expression of C-MYC and BCL11A had significantly lower survival rates compared to those with singular expression. Furthermore, BCL11A protein expression levels demonstrated significant associations with P53 and C-MYC protein expression levels in the Germinal Center B-cell-like (GCB) subtype. These findings suggest that BCL11A may serve as a potential prognostic marker and therapeutic target for DLBCL.</div></div>","PeriodicalId":19916,"journal":{"name":"Pathology, research and practice","volume":"264 ","pages":"Article 155717"},"PeriodicalIF":2.9,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142639439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dysplastic crypts with lateral buddings in tubular adenomas","authors":"Carlos A. Rubio ,&nbsp;Michael Vieth ,&nbsp;Corinna Lang-Schwarz","doi":"10.1016/j.prp.2024.155704","DOIUrl":"10.1016/j.prp.2024.155704","url":null,"abstract":"<div><div>Tubular adenomas (TA) are the most frequent of all colorectal adenomas. Current definitions of TA do not include the phenotype of the dysplastic crypts. We report a novel crypt phenotype characterized by dysplastic crypts with lateral buddings (DCLB). Out of the 309 TA, 25.9 % (n=80) exhibited DCLBs: 12.5 % (n=10) had one DCLB focus/TA, 15.0 % (n=12) had two DCLB foci/TA, 27.5 % (n=22) three had three DCLB foci/TA, 30.0 % (n=24) had four DCLB foci/TA, 12.5 % (n=10) had five DCLB foci/TA, and in the remaining 2.5 %n (n=2) most fields of view at x4 showed DCLB foci. DCLB in TA were generated independently of TA size or degree of dysplasia. The presence of DCLB was not influenced by age, gender or localization. In conclusion, a novel histologic phenotype of TA is showcased. DCLBs are integral components in some of the TA. Recently, another novel dysplastic crypt phenotype in TA characterized by dysplastic crypts in tandem was reported. The awareness that different dysplastic crypt phenotypes thrive in TA might open a new vista on research aimed to learn more about why the most prevalent of all colorectal adenomas thrive with a low capacity to invade the host.</div></div>","PeriodicalId":19916,"journal":{"name":"Pathology, research and practice","volume":"264 ","pages":"Article 155704"},"PeriodicalIF":2.9,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142625776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}